Advertisement

Der Schmerz

, Volume 24, Issue 6, pp 621–624 | Cite as

Analgetische Therapie mit Levomethadon bei Kalziphylaxie

Eine Kasuistik
  • M. PoelsEmail author
  • R. Joppich
  • K. Gerbershagen
  • F. Wappler
Kasuistiken

Zusammenfassung

Die Kalziphylaxie („calcific uremic arteriopathy“) ist eine seltene Komplikation der terminalen Niereninsuffizienz. Sie ist gekennzeichnet durch Verkalkungen der Arteriolen und sehr schmerzhaften, ischämischen Hautulzerationen. Im Rahmen der symptomatisch ausgerichteten Behandlung kommt der Schmerztherapie eine besondere Bedeutung zu. Übliche analgetische Konzepte erweisen sich meist als unzureichend, was den extremen Leidensdruck der Patienten verstärkt. In diesem Fallbericht wird die erfolgreiche analgetische Therapie bei Kalziphylaxie mit Levomethadon beschrieben.

Schlüsselwörter

Kalziphylaxie Schmerzmanagement Opioidanalgetika Methadon 

Analgesic therapy of calciphylaxis with levomethadone

A case study

Abstract

Calciphylaxis, or calcific uremic arteriopathy, is a rare complication of end-stage renal impairment. It is characterized by calcification of arterioles and development of intensely painful subcutaneous ischemic ulcerations. While symptomatic management is the mainstay of treatment, particular emphasis is placed on adequate analgesia. Conventional analgesic concepts have mostly proved to be insufficient which increases the extreme suffering of patients. This case report describes the successful analgesic treatment of calciphylaxis with levomethadone.

Keywords

Calciphylaxis Analgesia Opioid analgesics Methadone 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Rogers NM, Coates PTH (2008) Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 17(6):629–634CrossRefPubMedGoogle Scholar
  2. 2.
    Mazhar AR, Johnson RJ, Gillen D et al (2001) Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60(1):324–332CrossRefPubMedGoogle Scholar
  3. 3.
    Polizzotto MN, Bryan T, Ashby MA, Martin P (2006) Symptomatic management of calciphylaxis: a case series and review of the literature. J Pain Symptom Manage 32(2):186–190CrossRefPubMedGoogle Scholar
  4. 4.
    Ketteler M, Schlieper G, Floege J (2006) Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 47(6):1027–1034CrossRefPubMedGoogle Scholar
  5. 5.
    Schlieper G, Brandenburg V, Ketteler M, Floege J (2009) Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol 5(9):539–543CrossRefPubMedGoogle Scholar
  6. 6.
    Schliep S, Schuler G, Kiesewetter F (2008) Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol 18(5):554–556PubMedGoogle Scholar
  7. 7.
    Podymow T, Wherrett C, Burns KD (2001) Hyperbaric oxygen in the treatment of calciphylaxis: a case series. Nephrol Dial Transplant 16(11):2176–2180CrossRefPubMedGoogle Scholar
  8. 8.
    Llach F, Velasquez Forero F (2001) Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 38(5 Suppl 5):S20–S33CrossRefPubMedGoogle Scholar
  9. 9.
    Elsner F, Sabatowski R, Radbruch L (2000) Emergency pain treatment – ambulatory intravenous morphine titration in a patient with cancer pain. Anasthesiol Intensivmed Notfallmed Schmerzther 35(7):462–464CrossRefPubMedGoogle Scholar
  10. 10.
    Nauck F, Ostgathe C, Dickerson ED (2001) A German model for methadone conversion. Am J Hosp Palliat Care 18(3):200–202CrossRefPubMedGoogle Scholar
  11. 11.
    Green JA, Green CR, Minott SD (2000) Calciphylaxis treated with neurolytic lumbar sympathetic block: case report and review of the literature. Reg Anesth Pain Med 25(3):310–312PubMedGoogle Scholar
  12. 12.
    Davison SN, Mayo PR (2008) Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. J Opioid Manag 4(6):335–336, 339–344PubMedGoogle Scholar
  13. 13.
    Lobo ED, Heathman M, Kuan H et al (2010) Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials. Clin Pharmacokinet 49(5):311–321CrossRefPubMedGoogle Scholar
  14. 14.
    Randinitis EJ, Posvar EL, Alvey CW et al (2003) Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 43(3):277–283CrossRefPubMedGoogle Scholar
  15. 15.
    Inturrisi CE (2005) Pharmacology of methadone and its isomers. Minerva Anestesiol 71(7–8):435–437Google Scholar
  16. 16.
    Matsui A, Williams JT (2010) Activation of micro-opioid receptors and block of K3(IR) potassium channels and NMDA receptor conductance by l- and d-methadone in rat locus coeruleus. Br J Pharmacol [Epub ahead of print]Google Scholar
  17. 17.
    Mercadante S, Arcuri E (2005) Hyperalgesia and opioid switching. Am J Hosp Palliat Care 22(4):291–294CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • M. Poels
    • 1
    Email author
  • R. Joppich
    • 1
  • K. Gerbershagen
    • 2
  • F. Wappler
    • 1
  1. 1.Klinik für Anästhesiologie und Operative Intensivmedizin, Krankenhaus MerheimKlinikum der Privaten Universität Witten/HerdeckeKölnDeutschland
  2. 2.Klinik für Neurologie und PalliativmedizinKliniken der Stadt Köln gGmbHKölnDeutschland

Personalised recommendations